Currently, no ovarian cancer screening test with high sensitivity and specificity exists. In a recent proof-of-concept study published in Nature Biomedical Engineering, a uniquely designed microfluidic nanochip detected low levels of ovarian cancer–associated markers in blood. If validated in large trials, the technology could be used for early detection of the cancer, which is currently diagnosed at late clinical stages in approximately 85% of patients.